Consolidated Balance Sheets - USD ($)
$ in Thousands |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Current assets: |
|
|
| Cash and cash equivalents [note 7] |
$ 43,022
|
$ 35,853
|
| Grant receivable [note 4] |
153
|
|
| Prepaid expenses and other assets |
1,419
|
1,122
|
| Total current assets |
44,594
|
36,975
|
| Other assets and restricted cash [note 7, note 8 and note 9] |
183
|
279
|
| Right-of-use assets [note 13] |
64
|
146
|
| License agreement [note 5 and 6] |
1,641
|
1,864
|
| Goodwill [note 5] |
1,034
|
1,034
|
| Total assets |
47,516
|
40,298
|
| Current liabilities: |
|
|
| Accounts payable |
841
|
332
|
| Accrued liabilities other |
348
|
584
|
| Accrued clinical liabilities |
1,352
|
453
|
| Accrued compensation |
1,940
|
1,474
|
| Current portion of long-term obligations [note 13] |
69
|
92
|
| Total current liabilities |
4,550
|
2,935
|
| Convertible debt [note 10] |
14,920
|
|
| Long-term obligations [note 13] |
4
|
77
|
| Total liabilities |
19,474
|
3,012
|
| Commitments and contingencies [note 13] |
|
|
| Stockholders' equity: |
|
|
| Common stock, $0.001 par value, 150,000,000 shares authorized, 9,453,542 and 6,111,735 issued and outstanding at December 31, 2021 and December 31, 2020, respectively. |
79
|
76
|
| Additional paid-in capital |
121,545
|
97,640
|
| Accumulated deficit |
(93,586)
|
(60,434)
|
| Accumulated other comprehensive income |
4
|
4
|
| Total stockholders' equity |
28,042
|
37,286
|
| Total liabilities and stockholders' equity |
47,516
|
40,298
|
| Series A Convertible Preferred Stock [Member] |
|
|
| Stockholders' equity: |
|
|
| Convertible preferred stock, value |
|
|
| Series B Convertible Preferred Stock [Member] |
|
|
| Stockholders' equity: |
|
|
| Convertible preferred stock, value |
|
|